CARES Act Provider Relief Fund Compliance Podcast Series
Part II - Terms and Conditions: What You Should Know and Do To Demonstrate Compliance
Through the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Paycheck Protection Program and Health Care Enhancement Act, $175 billion has been appropriated to the Provider Relief Fund. HHS has or will pay out these relief funds as grants to healthcare providers in order to prevent, prepare for, and respond to COVID-19. This three part podcast series will discuss Provider Relief Fund requirements, the rules on how grant monies are to be spent and accounted for and how to best position your organization for future federal audits and enforcement activities.
In Part II, we discuss the terms and conditions of the Provider Relief Fund and important policies, processes and documentation to mitigate risk and demonstrate compliance.
Listen to the podcast here.
For other podcasts in this series:
Click here to listen to Part I, where we provide an overview of the Provider Relief Fund, the oversight structure and key compliance considerations that recipients should keep in mind when accepting these funds.
The Most Undervalued Asset in Health Systems Isn’t a Building — It’s the Physician Enterprise
April 30, 2026
Health systems often look to buildings or rates for growth, but the strongest lever is frequently overlooked. This perspective reframes the physician enterprise as a scalable growth platform, and shows how leaders can unlock margin, resilience, and long-term value.
Access Reimagined: Meeting Evolving Workforce Expectations While Expanding Patient Reach
April 23, 2026
Redesign the system. Realign incentives. Reimagine access. Patrick J. Byrne, M.D., Chief of Cleveland Clinic's Integrated Surgical, and Lisa Ishii, M.D., M.H.S, SVP of Operations for Johns Hopkins Health System join A&M Healthcare Industry Group's Brian Giessler to share their vision for redesigning healthcare to deliver the right care at the right time.
LS: Next Growth Curve
April 22, 2026
Developed markets are facing structural headwinds, such as affordability constraints, pricing reform, as demographic saturation and slower volume growth are limiting expansion and resulting a moderating growth rate. In contrast, emerging markets are entering a phase of healthcare formalization and access expansion driven by rising chronic disease burden and government prioritization of pharmaceuticals
The Next Growth Curve: How Biopharma Can Win in Developing Markets
April 20, 2026
Developed markets are facing structural headwinds, such as affordability constraints, pricing reform, as demographic saturation and slower volume growth are limiting expansion and resulting a moderating growth rate. In contrast, emerging markets are entering a phase of healthcare formalization and access expansion driven by rising chronic disease burden and government prioritization of pharmaceuticals
